RE:RE:RE:MBC phase 3
Also form the AN agreement
One common share purchase warrant of USD $2 million whereby, upon exercise, Adlai may purchase Oncolytics' common shares priced at a 120% premium of the five-day weighted average closing price immediately preceding the exercise date. Oncolytics has the right to call this warrant when the first patient is enrolled in the phase 3 mBC study or six months after execution of The Agreement, whichever is later.
It does clearly state when the 1st patient of the phase 3 mbc trial and if you are correct about the inclusion of all the trials leading up to this then why has this payment to onc not been announced and exercised.
So my take is that it is only on the start of an actual phase 3 trial which may not be until late 2024 or 2025 as the company is still seeking guidance from the fda and expects to hear back sometime in the next 6-9 months and then the trial sites would need to be set up and of course a partner on top of it all....
Having said all that I can still see a partner for panc (although onc has stated that they want a partner for both indications) sooner than later and especially if ESMO results confirm all we have been hoping for.
A BO is still the holy grail for the company as it removes all wait and doubt for the company and shareholders.